Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

----------------------------------------

Deficit, end of period (38,934,651) (26,819,421) (38,934,651)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Loss per share - basic and

diluted (0.08) (0.07)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average common shares

outstanding 47,062,644 44,750,964

-------------------------------------------------------------------------

-------------------------------------------------------------------------

ARIUS RESEARCH INC.

(A DEVELOPMENT STAGE COMPANY)

INTERIM STATEMENTS OF CASH FLOWS

(Unaudited)

-----------------------------------------------------------

Six-month Six-month

period ended period ended

May 31, May 31,

2008 2007

$ $

-----------------------------------------------------------

Cash provided by (used in):

Operating activities:

Loss for the period (6,401,018) (5,342,827)

Items not involving cash:

Amortization of:

Facilities and equipment 187,307 166,479

Deferred costs - -

Leasehold inducements (20,743) (20,743)

Loss on disposal of equipment - -

Write-off of leasehold

improvements - -

Write-off of receivable 42,109
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
(Date:10/20/2014)... Rochelle, Virginia (PRWEB) October 20, 2014 ... of NDA Partners LLC, announced today that Ellen ... and legal support for the pharmaceutical industry, has ... and manager of its legal services practice. ... reports and expert witness and testimony, to top ...
(Date:10/19/2014)... October 19, 2014 The Latin American ... market in Latin America with analysis and forecast of ... 2013, and is expected to reach $2,366.8 million by ... 2018. , Browse through the TOC of the Latin ... of the in-depth analysis provided. It also provides a ...
(Date:10/19/2014)... 19, 2014 NextCODE Health, which enables clinicians and ... real time, today announced the launch of its new genomic ... at the American Society of Human Genetics (ASHG) annual meeting ... sign up and apply for free beta access, visit ... benefits can be viewed here . The ...
Breaking Biology Technology:PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... Nov. 3 Portola,Pharmaceuticals, a biopharmaceutical company ... cardiovascular and inflammatory,diseases, and cancer, today announced ... large Phase II clinical trial of betrixaban, ... for stroke prevention in patients with,atrial fibrillation ...
... Phase 2, clinical trial indicate statistically significant reduction in recurrences ... ... PRINCETON, N.J. and JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/,-- Medarex, Inc. ... University of Massachusetts Medical School (UMMS) today,announced that a Phase 2 ...
... Nov. 3 Cepheid (Nasdaq:,CPHD) today announced ... agreement to,acquire Stretton Scientific Limited, a privately ... equipment based in,Stretton, England. Stretton Scientific currently ... life science products, to,a broad group of ...
Cached Biology Technology:Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 2Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 3Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 4Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 2Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 3Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 4Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 5Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 6Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 2Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 3
(Date:10/15/2014)... The book ,Models of Life, is a non-traditional biophysics ... itself. The book is a journey of discovery into ... of life and biological regulation. It is about how ... strategic communication between the billions of cells in an ... the relationships between principles, which can be found on ...
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/15/2014)... Lithuania , Oct. 15, 2014   ... technologies, today announced the availability of the ... VeriLook Surveillance 3.0 provides real-time biometric face identification ... high-resolution digital surveillance cameras. The new version not ... and differentiates people from objects while they are ...
Breaking Biology News(10 mins):New book about life as seen from physics 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... planktonic microbes living throughout the water column in the ... specialization of microbial communities at each depth--ranging from 40 ... information stored in the genomes of entire microbial communities, ... marine ecosystem," said MIT's Ed DeLong, who led the ...
... Center scientists have demonstrated a new technology that accurately ... coli bacteria. , The unique technology uses a protein ... system that also includes a silicon chip and a ... an article on the technology in its February issue. ...
... succeeded in growing mature taste receptor cells outside the body ... keep the cells alive for a prolonged period of time. ... of new opportunities to increase scientists' understanding of the sense ... disease. , "We have an important new tool to help ...
Cached Biology News:Vaccine provides 100 percent protection against avian flu virus in animal study 2Vaccine provides 100 percent protection against avian flu virus in animal study 3Rochester scientists develop fast-working biosensor 2Living taste cells produced outside the body 2Living taste cells produced outside the body 3
... Buffer is a convenient, premixed, ... samples and Perfect RNA Markers. ... no dilution and is suitable ... Simply mix equal volumes of ...
... cells were cultured in DMEM and harvested at ... to keep the antigens in their native forms, ... are arrayed on a 12-well (5 mm) adhesive ... to enhance cellular attachment and to minimize background ...
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
... 3T3 cells were cultured in DMEM with 4 ... of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on ... each wells surface specifically treated to enhance cellular ...
Biology Products: